Conversations in Lung Cancer Research

Thoracic Oncology Group Of Australasia (TOGA)
  • 0.0 (0)
  • Medicine
  • Updated Biweekly

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

  1. Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

    Jun 25

    Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

    In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Welcome and Acknowledgement (01:33) Panel Introductions (02:52) First Reactions in Clinic (05:01) Frontline NSCLC Evidence (06:48) Who Gets Ipi Nivo? (11:29) Chemo Free and Rechallenge (15:20) Stopping or Continuing IO (20:34) Mesothelioma Treatment Choices (27:20) Small Cell Reality Check (30:21) Thymic Malignancies Debate (34:54) Governance and Toxicity Safety (38:44) Survivorship and Follow Up (43:43) Real World Data Next Steps (48:05) Wrap Up Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    49 min
  2. Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

    Jun 18

    Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

    In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 CM9LA https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/abstract CM227-https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1%   (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    28 min
  3. The Evolving Landscape of BRAF-Mutated NSCLC in Australia

    Jun 4

    The Evolving Landscape of BRAF-Mutated NSCLC in Australia

    In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide, leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer. Joined by Prof Ahn Myung-ju, a Medical Oncologist at Hanyang University Medical Centre in South Korea as well as Co-chair for the upcoming World Lung Cancer Conference, and A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital in Sydney. The panel discusses the clinical characteristics and incidence of this molecular subset, the critical need for upfront comprehensive genomic testing, key clinical trial data for targeted therapies, and practical strategies for managing treatment-specific side effects like pyrexia syndrome. This episode is sponsored by Pierre Fabre.   (00:00) Welcome and Acknowledgement (00:47) Introducing the Topic and Panel (01:56) BRAF Incidence Overview (02:43) Testing Pathways in Australia (06:16) Mutation Classes and Tools (07:47) Korea Testing Perspective (09:03) Pivotal Targeted Therapy Trials (13:33) Choosing First Line Treatment (16:40) Australian Sequencing Approach (20:23) Managing Pyrexia and Toxicities (25:49) Wrap Up Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    27 min
  4. Thymic Cancer: The Lesser-Known Thoracic Tumours

    May 21

    Thymic Cancer: The Lesser-Known Thoracic Tumours

    In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital and Chris O'Brien Lifehouse , leads a practical overview of managing thymic cancers in Australia and New Zealand. She is joined by an expert panel featuring Prof Steven Kao, a thoracic medical oncologist at Chris O'Brien Lifehouse, Dr. Felicity Meikle, a cardiothoracic surgeon at the Waikato District Health Board in Hamilton, and Dr. Dasantha Jayamanne, a radiation oncologist at Royal North Shore Hospital and Genesis Care in Sydney. Despite being a "forgotten area" in thoracic oncology, these rare tumours remain a key focus for research and multidisciplinary care. (00:00) Introducing the Topic and Experts (02:10) Epidemiology and Risk Factors (04:26) Symptoms and Initial Workup (06:40) PET Scans and Biopsy Decisions (11:40) Pathology and Staging Basics (15:05) MDT Strategy (16:08) Postoperative Treatment (19:46) Perioperative Systemic Therapy (23:08) Stage IV Management and Surgery (25:47) Immunotherapy in Thymic Carcinoma (34:51) Next Line and Targeted Options (42:04) Wrap Up and Thanks Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    43 min
  5. A/Prof Surein Arulananda: A Masterclass in Career Growth

    May 7

    A/Prof Surein Arulananda: A Masterclass in Career Growth

    In this episode of TOGA's 'Conversations in Lung Cancer Research,' A/Prof Mel Moore interviews A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health and Convenor at the 2026 TOGA ASM. They discuss his academic background, his unexpected journey into oncology, a fellowship in Boston and MBA in London and his vision for the future of lung cancer treatment. [0:00] Introduction [2:05] Career Foundations [3:19] Choosing Oncology  [6:39] Translational PhD  [12:00] Finding the Balance  [13:36] The Boston Fellowship [18:00] The MBA Journey in London [25:35] Targeted Therapies + SCLC [30:10] Convening the TOGA ASM [32:53] Future Ambitions Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    37 min
  6. TOGA ASM 2026: Program Review

    Apr 16

    TOGA ASM 2026: Program Review

    In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Surein Arulananda (Medical Oncologist, Monash Health) is joined by members of the Local Organising Committee to provide an exclusive preview of the 2026 TOGA Annual Scientific Meeting (ASM). The panel discusses the most anticipated sessions, emerging themes in thoracic oncology, and the evolving landscape of lung cancer care in Australia and New Zealand. (00:00) Welcome and Acknowledgement (00:40) Meet the Panel (01:21) Nursing Priorities (02:09) Precision Survivorship (03:25) Respiratory Viewpoint (05:22) Nodule Management (06:46) Radiation Oncology Sessions (09:22) Must See Immunotherapy (11:42) Small Cell Spotlight (12:45) One Session for Everyone (14:45) Debates and AI (17:30) Closing Thanks Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    18 min
  7. ALK TKI Sequencing in the Australian Landscape

    Apr 9

    ALK TKI Sequencing in the Australian Landscape

    In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually. (00:00) Welcome and Acknowledgement (00:43) Meet the Expert Guests (01:40) ALK History and Breakthroughs (03:48) Who Gets ALK Lung Cancer (04:57) Workup and Staging Essentials (05:54) Patterns of Spread and Clots (07:24) Second Generation TKIs Standard (09:03) Long Term Toxicities (11:07) Progression Assessment and LAT (12:50) Lorlatinib After Progression (15:46) Lorlatinib First Line Crown Data (17:11) Choosing and Dosing Lorlatinib (20:55) Managing Lorlatinib Side Effects (22:29) Predicting Response and Follow Up (29:30) Next Generation Inhibitors NAL (32:04) Early Stage and Adjuvant TKIs (36:32) Beyond TKIs Chemo and ADCs (39:30) Patient Support and Closing Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    41 min
  8. Professor Michael Millward: Clinical Insights in Lung Cancer Research

    Feb 26

    Professor Michael Millward: Clinical Insights in Lung Cancer Research

    In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore talks with Prof Michael Millward, Foundation Professor of Clinical Cancer Research at the University of Western Australia and the oncology Medical Director at Linear Clinical Research in Perth. They discuss Prof Millward's extensive background in clinical and research interests in lung cancer and melanoma, the evolution of clinical trials, and the future of medical oncology, touching on molecular diagnostics, liquid biopsies, and early phase drug development. Millward also shares personal anecdotes and practical advice for young oncologists seeking to integrate clinical research into their careers. (00:00) Introduction and Acknowledgements (00:31) Guest Introduction: Professor Michael Millward (01:49) Early Career and Training (05:23) Specialisation in Oncology (08:15) Advancements in Molecular Oncology (15:03) Building a Phase One Unit (21:37) Mentorship and Future of Clinical Trials (28:23) Future of Lung Cancer Treatment (30:33) Closing Remarks and Final Thoughts   Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    33 min
See All (71)

Trailer

About

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

Information

  • Creator
    Thoracic Oncology Group Of Australasia (TOGA)
  • Years Active
    2020 - 2026
  • Episodes
    71
  • Rating
    Clean
  • Copyright
    Copyright © 2026 TOGA – Thoracic Oncology Group Australasia. No part of this podcast may be reproduced without our written permission.
  • Show Website
    Conversations in Lung Cancer Research

You Might Also Like